Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ImageneBio, Inc.

Get SEC filing alerts via email and in your feed for ImageneBio, Inc.

IKNA IMA

ImageneBio, Inc.

About ImageneBio, Inc.

Ikena Oncology Inc. develops targeted cancer therapies focusing on molecular pathways such as RAS and RAF. Its lead candidate, IK-595, is a dual MEK-RAF inhibitor aimed at treating RAS pathway-driven cancers. The company advances its pipeline through clinical trials, collaborates with biotech partners, and relies on intellectual property protections. It seeks regulatory approval for innovative oncology drugs and explores strategic alternatives to maximize shareholder value.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from ImageneBio, Inc.

1
1
ImageneBio, Inc. ImageneBio Reports $10.6 Million Net Loss in Q1 2026, Increased Operating Expenses

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
ImageneBio, Inc. ImageneBio Reports Fiscal Year 2025 Results Post-Merger with Inmagene Biopharmaceuticals

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
ImageneBio, Inc. ImageneBio Reports $24.8 Million Net Loss in Q3 2025, Increases R&D Spending

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
ImageneBio, Inc. Ikena Oncology Reports Reduced Net Loss and Increased Cash Reserves in Q2 2025

Via official filing (AI summary) | 11 months ago | 0 comments

5
1
ImageneBio, Inc. Ikena Oncology Reports $8.6 Million Net Loss in Q1 2025, Plans Merger with Inmagene Biopharmaceuticals

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
ImageneBio, Inc. Ikena Oncology Reports $49.2 Million Net Loss, Plans Merger with Inmagene

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
ImageneBio, Inc. Ikena Oncology Reports Significant Financial Changes, Decline in Cash and Cash Equivalents in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments